<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517087</url>
  </required_header>
  <id_info>
    <org_study_id>120060</org_study_id>
    <secondary_id>12-N-0060</secondary_id>
    <nct_id>NCT01517087</nct_id>
  </id_info>
  <brief_title>Studying Motor Neuron Tests</brief_title>
  <official_title>Structural and Functional Brain Imaging Markers of Upper Motor Neuron Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - People with motor neuron disorders have changes in the parts of the brain that control&#xD;
      movement. Some tests that are currently used to study these changes are magnetic resonance&#xD;
      imaging (MRI) and transcranial magnetic stimulation (TMS). We don t know if MRI scans and TMS&#xD;
      give the same results if done at different times in the same person. Researchers want to see&#xD;
      if these tests produce different results if given to healthy adults on two separate&#xD;
      occasions.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To test the reliability of different tests of the brain used to study motor neuron&#xD;
      disorders.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  &lt;TAB&gt;Healthy individuals at least 35 years of age who have no history of neurological&#xD;
           disorders and take no medications.&#xD;
&#xD;
        -  &lt;TAB&gt;Pregnant women may not participate.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a medical history and physical exam.&#xD;
&#xD;
        -  Participants will have two testing visits 1 to 6 months apart.&#xD;
&#xD;
        -  The first visit will have three parts. The first part is a neurological exam to test&#xD;
           strength, sensation, reflexes, and coordination of movement. The second part will be TMS&#xD;
           tests. The third part will involve an MRI scan to study the parts of the brain that&#xD;
           control movement.&#xD;
&#xD;
        -  At the second visit, participants will have MRI scanning only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      The objective of the protocol is to determine the test-retest reliability of imaging&#xD;
      techniques that measure the structural and functional integrity of the motor cortex in&#xD;
      healthy subjects. Our goal is to determine whether such measures are sufficiently&#xD;
      reproducible that they may be used to follow disease progression over time in patients with&#xD;
      motor neuron disease. A second objective is to obtain age-matched normative data to provide&#xD;
      reference values for studies examining the correlation of physiological and clinical&#xD;
      measurements of motor function, cognitive testing, and plasma and spinal fluid biomarker&#xD;
      measures with disease progression in patients with motor neuron disease.&#xD;
&#xD;
      Study Population&#xD;
&#xD;
      55 neurologically normal, healthy adults, age 35 or older&#xD;
&#xD;
      Design&#xD;
&#xD;
      Each subject will undergo several sessions of testing. The first testing session will consist&#xD;
      of a clinical examination with measurements of movement speed. Subjects will undergo one&#xD;
      session with transcranial magnetic stimulation of the brain, one session of cognitive&#xD;
      testing, and three sessions of magnetic resonance imaging of the brain, one to eighteen&#xD;
      months apart. Subjects may opt-in for collection of blood and spinal fluid to provide&#xD;
      controls for biomarker studies in motor neuron disease patients.&#xD;
&#xD;
      Outcome Measures&#xD;
&#xD;
      The primary outcome is the test-retest reliability of magnetic resonance imaging measurements&#xD;
      of the motor cortex in individual subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">November 25, 2020</completion_date>
  <primary_completion_date type="Actual">November 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test-retest reliability of MRI measures</measure>
    <time_frame>09/30/2019</time_frame>
    <description>The test-retest reliability will be assessed by calculating the intraclass correlation coefficient (ICC) between the two sessions. An ICC &gt; 0.8 is considered to indicate excellent reliability.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>Central Nervous System</condition>
  <condition>Volunteer</condition>
  <condition>Neurological Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>neurologically normal, healthy adults, age 35 or older.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        55 neurologically normal, healthy adults, age 35 or older.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Healthy adults aged 35 and older&#xD;
&#xD;
          -  No history of a neurological disorder&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Treatment within the preceding week with medications that affect neuronal&#xD;
             excitability, such as antidepressants, sedatives, and drugs for epilepsy or migraine.&#xD;
&#xD;
          -  Change in blood pressure medications within the preceding week.&#xD;
&#xD;
          -  Metal in the body such as pacemakers, implanted pumps or other implanted electronic&#xD;
             devices, some types of dental implants, aneurysm clips (metal clips on the wall of a&#xD;
             large artery), metallic prostheses (including metal pins and rods, heart valves, and&#xD;
             cochlear implants), permanent eyeliner or shrapnel fragments.&#xD;
&#xD;
          -  Pregnancy. Women of childbearing potential will undergo urine pregnancy testing before&#xD;
             MRI scanning.&#xD;
&#xD;
          -  Fear of confined spaces.&#xD;
&#xD;
          -  Serious medical illness.&#xD;
&#xD;
          -  Employees or staff in the investigator's section.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Kay Floeter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-N-0060.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Ellis CM, Simmons A, Jones DK, Bland J, Dawson JM, Horsfield MA, Williams SC, Leigh PN. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 1999 Sep 22;53(5):1051-8.</citation>
    <PMID>10496265</PMID>
  </reference>
  <reference>
    <citation>Tartaglia MC, Laluz V, Rowe A, Findlater K, Lee DH, Kennedy K, Kramer JH, Strong MJ. Brain atrophy in primary lateral sclerosis. Neurology. 2009 Apr 7;72(14):1236-41. doi: 10.1212/01.wnl.0000345665.75512.f9.</citation>
    <PMID>19349603</PMID>
  </reference>
  <reference>
    <citation>Wong JC, Concha L, Beaulieu C, Johnston W, Allen PS, Kalra S. Spatial profiling of the corticospinal tract in amyotrophic lateral sclerosis using diffusion tensor imaging. J Neuroimaging. 2007 Jul;17(3):234-40.</citation>
    <PMID>17608909</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrospinal Fluid</keyword>
  <keyword>Magnetic Resonance Spectroscopy</keyword>
  <keyword>Transcranial Magnetic Stimulation (TMS)</keyword>
  <keyword>Diffusion Tensor Imaging</keyword>
  <keyword>Functional Magnetic Resonance Imaging (fMRI)</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

